98%
921
2 minutes
20
Longitudinal data on the immune response from the first dose to several months after the third dose of COVID-19 vaccine are limited. We analyzed the immune response in 406 Japanese healthcare workers who received at least three doses of vaccine. The geometric mean anti-receptor binding domain IgG antibody titers and antigen-stimulated T-cell interferon-gamma levels after 6 months after receiving a third dose were similar to those 8 weeks after receiving a second dose. Humoral and cellular immunity induced by the third dose was more durable than that induced by the second dose. UMIN Clinical Trials Registry ID: UMIN000043340.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887493 | PMC |
http://dx.doi.org/10.1016/j.vaccine.2023.01.049 | DOI Listing |
Microbiol Spectr
September 2025
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Recently, to achieve cure, physicians have been resorting to overuse or misuse of antimicrobials to treat resistant infections, leading to the emergence of further resistant organisms. To overcome this issue, antimicrobial guidelines have been developed. Nevertheless, recently, controversy regarding the effect of adherence to antimicrobial guidelines on patient outcomes has been raised.
View Article and Find Full Text PDFJ Biochem Mol Toxicol
September 2025
Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, PR China.
Gastric cancer (GC) is the third leading cause of cancer mortality globally, often presenting with insidious symptoms that lead to late-stage diagnoses, underscoring the critical need for innovative diagnostic and therapeutic strategies. One such avenue is the exploration of ferroptosis, a regulated form of cell death implicated in various pathological conditions and malignancies. In this study, we demonstrate that brucine, an alkaloid derived from Strychnos nux-vomica, exerts significant antitumor effects on GC cells both in vitro and in vivo.
View Article and Find Full Text PDFAm J Prev Cardiol
September 2025
Department of Nutrition, School of Public Health, Guangzhou Medical University, Guangzhou, China.
Background: Evidence regarding the effect of physical activity (PA) on the risk of cardiovascular disease (CVD) among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is scarce. We aimed to clarify the role of PA in preventing CVD in patients with MASLD and provide insights into PA recommendations specific to this patient group.
Methods: This study conducted two cohort studies of 112,872 subjects with MASLD using questionnaire-measured PA data and 22,426 subjects with MASLD using accelerometer-measured PA data.
Diabetes Metab Res Rev
September 2025
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Aim: Our aim was to ascertain whether metformin can reduce insulin requirement without compromising glycaemic control during pregnancy in women with type 1 diabetes.
Methods: A total of 126 pregnant women with type 1 diabetes were recruited for a randomised, double-blind, placebo-controlled multicentre study. The primary outcome was total insulin change, defined as the difference between baseline and third trimester maximum insulin dose (IU).
J Thromb Haemost
September 2025
Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Background: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs.
View Article and Find Full Text PDF